NEW YORK, Aug. 25, 2017 /PRNewswire/ -- Bernstein Liebhard
LLP today announced that only 10 days remain to file a motion for
lead plaintiff in a securities class action pending in the United
States District Court for the District of New Jersey on behalf of a class (the "Class")
consisting of all persons or entities who purchased the securities
of Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ:
OCUL) during the period between March 10,
2016 and July 11, 2017,
inclusive (the "Class Period"). The complaint alleges that
Defendants violated Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934.
The complaint alleges that, throughout the class period,
Defendants issued materially false and/or misleading statements
and/or failed to disclose that: (i) Ocular failed to adequately
address issues identified in the First Form 483; (ii) Ocular's
re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company
could not timely and adequately address the FDA-identified
manufacturing and control issues; (iii) Ocular's continued
manufacturing issues imperil the approval of DEXTENZA; and (iv) as
a result, Defendants' public statements were materially false and
misleading at all relevant times.
Plaintiffs seek to recover damages on behalf of all Class
members who invested in Ocular securities during the Class
Period. If you invested in Ocular securities as described
above, and lost money on the transactions, you may wish to join in
this action to serve as lead plaintiff. In order to do so,
you must meet certain requirements set forth in the applicable law
and file appropriate papers no later than September 5, 2017.
A "lead plaintiff" is a representative party that acts on behalf
of other class members in directing the litigation. In order
to be appointed lead plaintiff, the court must determine that the
class member's claim is typical of the claims of other class
members, and that the class member will adequately represent the
class. Under certain circumstances, one or more class members
may together serve as lead plaintiff. Your ability to share
in any recovery is not, however, affected by the decision whether
or not to serve as a lead plaintiff. You may retain Bernstein
Liebhard LLP, or other counsel of your choice, to serve as your
counsel in this action.
If you are interested in discussing your rights as an Ocular
investor and/or have information relating to the matter, please
contact Joseph R. Seidman, Jr. at
(877) 779-1414 or seidman@bernlieb.com.
Bernstein Liebhard LLP has pursued hundreds of securities,
consumer and shareholder rights cases and recovered over
$3.5 billion for its clients.
The Firm has been named to the National Law Journal's "Plaintiffs'
Hot List" thirteen times.
You can obtain a copy of the complaint from the clerk of the
court for the United States District Court for the District of
New Jersey.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law
firm responsible for this advertisement is Bernstein Liebhard LLP,
10 East 40th Street, New York, New
York 10016, (212) 779-1414. The lawyer responsible for this
advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
Contact Information
Joseph R. Seidman, Jr.
Bernstein Liebhard LLP
http://www.bernlieb.com
(212) 779-1414
seidman@bernlieb.com
View original
content:http://www.prnewswire.com/news-releases/bernstein-liebhard-llp-announces-that-only-10-days-remain-to-file-a-motion-for-lead-plaintiff-in-a-class-action-filed-against-ocular-therapeutix-inc-300509725.html
SOURCE Bernstein Liebhard LLP